Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022 07:55 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
December 11, 2022 09:00 ET
|
Senti Biosciences, Inc.
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is...
Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
November 23, 2022 07:55 ET
|
Senti Biosciences, Inc.
– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and...
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
November 10, 2022 07:55 ET
|
Senti Biosciences, Inc.
- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for...
Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
November 03, 2022 09:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces New Employment Inducement Grants
October 28, 2022 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting
October 05, 2022 08:01 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference
September 20, 2022 16:02 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:01 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Biosciences Announces New Employment Inducement Grants
August 19, 2022 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...